Liver cirrhosis. How to extend the life of patient?
https://doi.org/10.21518/2079-701X-2015-13-76-79
Abstract
Current approach to the problem of liver cirrhosis and management of patients is described. Basic pharmacological groups and drugs used in the treatment of patients with liver cirrhosis are characterized. The focus is on the relevance of competent selection of medicines for the treatment of comorbid diseases in patients with liver cirrhosis. Conclusion: at the stage of cirrhosis, symptomatic treatment approach - a timely and proper management of the symptoms and complications of liver cirrhosis - could extend patient's life and improve its quality.
About the Authors
M. F. Osipenko
Novosibirsk State Medical University
Russian Federation
Russian Federation
E. A. Bikbulatova
Novosibirsk State Medical University
Russian Federation
Russian Federation
S. I. Kholin
Novosibirsk State Medical University
Russian Federation
Russian Federation
References
1. PLeis JR, Lucas JW. Summary Health Statistics for U.S. AduLts: National Health Interview Survey, 2007. National Center for Health Statistics, 2009, 10.
2. Davis GL, Alter M, EL-Serag H, Poynard T Jennings L. Aging of Hepatitis C Virus (HCV)-infected Persons in the United States: A MuLtipLe Cohort Model of HCV Prevalence and Disease Progression. Gastroenterology, 2010. 138: 513-21.
3. SingLa A, Hart J, Youfu L, Tseng J, Shah S. HospitaLization for CompLications of Cirrhosis: Does VoLume Matter. J Gastrointest Surg, 2011. 15: 330-5.
4. Ahmed Mahmoud EL-TawiL. Treatment of porta! hypertension. World J Gastroenterol, 2012. March 21. 18(11): 1166-1175.
5. Prevention and management of gastroesopha-geaL varices and variceaL hemorrhage in cirrhosis. AASLD practice guideLines.
6. EASL cLinicaL practice guideLines on the management of ascites, spontaneous bacteriaL peritonitis, and hepatorenaL syndrome in cirrhosis. Journal of Hepatology, 2010, 53: 397-417,
7. Nusrat S, Khan MS, FaziLi J, Madhoun M. F. Cirrhosis and its compLications: Evidence based treatment. World J Gastroenterol, 2014 May 14. 20(18): 5442-5460.
8. Singh V, Singh A, Singh B, Vijayvergiya R, Sharma N, Ghai A, BhaLLa A. Midodrine and cLo-nidine in patients with cirrhosis and refractory or recurrent ascites: a randomized piLot study. Am J Gastroenterol, 2013. 108: 560-567.
9. RomaneLLi RG, La ViLLa G, BarLetta G, Vizzutti F, Lanini F, Arena U, Boddi V, Tarquini R, PantaLeo P, GentiLini P, Laffi G. Long-term aLbumin infusion improves survivaL in patients with cirrhosis and ascites: an unbLinded randomized triaL. World J Gastroenterol, 2006. 12: 1403-1407.
10. KaLambokis G, Mouzaki A, Rodi M, Tsianos E. Rifaximin for Prevention of Spontaneous BacteriaL Peritonitis. World J Gastroenterol, 2012. 18(4): 1700-2.
11. ALs-NieLsen B, GLuud LL, GLuud C. Non-absorbabLe disaccharides for hepatic encepha-Lopathy: systematic review of randomised triaLs. BMJ, 2004. 328: 1046.
12. Hepatic EncephaLopathy in Chronic Liver Disease: 2014 Practice guideLine by AASLD and EASL.
13. MuLLen KD, SanyaL A, Bass NM, Poordad F, Sheikh MY, Frederick RT, et aL. Long-term Safety and Efficacy of Rifaximin for the Maintenance of Remission from Overt Hepatic EncephaLopathy in Patients wtih Cirrhosis (submitted). Submitted. 2013.
14. Khungar V, Poordad F. Hepatic encephaLopa-thy. Clin Liver Dis, 2012. 16: 301-320.
15. Jennifer F.Frontera. Management of hepatic encephaLopathy. Current treatment options in neurology, May 2014. 16: 297.
16. ViLLa E, Camma C, Marietta M et aL. Enoxaparin prevents portaL vein thrombosis and Liver decompensation in patients with advanced cirrhosis. Gastroenterology, 2012. 143: 1253-1260. e1-4,
17. Amitrano L, Guardascione MA, Menchise A, Martino R, ScagLione M, Giovine S, Romano L BaLzano A. Safety and efficacy of anticoaguLa-tion therapy with Low moLecuLar weight hepa-rin for portaL vein thrombosis in patients with Liver cirrhosis. J Clin Gastroentero, 2010. 44: 448-451.
18. Garcia-Tsao G, SanyaL AJ, Grace ND, Carey WD. Prevention and management of gastroesopha-geaL varices and variceaL hemorrhage in cirrhosis. Am J Gastroenterol, 2007. 102: 20862102.
19. Argo CK, BaLogun RA. BLood products, voLume controL, and renaL support in the coaguLopathy of Liver disease. Clin Liver Dis, 2009. 13: 73-85.
20. HoLLand LL, Brooks JP. Toward rationaL fresh frozen pLasma transfusion: The effect of pLasma transfusion on coaguLation test resuLts. Am J Clin Pathol, 2006. 126: 133-139.
21. Martin-LLahi M, Pepin MN, Guevara M et aL. TerLipressin and aLbumin vs aLbumin in patients with cirrhosis and hepatorenaL syndrome: a randomized study. Gastroenterology, 2008. 134: 1352-1359.
22. EsraiLian E, Pantangco ER, KyuLo NL, Hu KO, Runyon BA. Octreotide/Midodrine therapy significantLy improves renaL function and 30-day survivaL in patients with type 1 hepatorenaL syndrome. Dig Dis Sci, 2007. 52: 742-748.
Review
For citations:
Osipenko MF, Bikbulatova EA, Kholin SI. Liver cirrhosis. How to extend the life of patient? Meditsinskiy sovet = Medical Council. 2015;(13):76-79. (In Russ.) https://doi.org/10.21518/2079-701X-2015-13-76-79
Views:
931
Email this article 